{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:47:48Z","timestamp":1791056868043,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"9-10","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.drudis.2009.02.006","type":"journal-article","created":{"date-parts":[[2009,2,26]],"date-time":"2009-02-26T05:35:29Z","timestamp":1235626529000},"page":"453-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Small molecule drug discovery for Huntington's Disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Wolfgang","family":"Fecke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gianfriddo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Gaviraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg C.","family":"Terstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2009.02.006_bib1","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1517\/13543784.16.12.1933","article-title":"Huntington's disease: progress and potential in the field","volume":"16","author":"Stack","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2009.02.006_bib2","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.drudis.2009.02.006_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"Sanchez","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2009.02.006_bib4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2009.02.006_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1749-6632.1999.tb07827.x","article-title":"Bioenergetics in Huntington's disease","volume":"893","author":"Grunewald","year":"1999","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.drudis.2009.02.006_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/mds.870110209","article-title":"Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory","volume":"11","author":"Taylor-Robinson","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2009.02.006_bib7","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","article-title":"Decreased expression of striatal signaling genes in a mouse model of Huntington's disease","volume":"9","author":"Luthi-Carter","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib8","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/hmg\/11.17.1939","article-title":"Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease","volume":"11","author":"Chan","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib9","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/hmg\/ddm133","article-title":"Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage","volume":"16","author":"Kuhn","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pneurobio.2007.03.004","article-title":"Transcriptional signatures in Huntington's disease","volume":"83","author":"Cha","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.drudis.2009.02.006_bib11","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","article-title":"Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease","volume":"296","author":"Dunah","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2009.02.006_bib12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/MCB.22.5.1277-1287.2002","article-title":"Interaction of Huntington disease protein with transcriptional activator Sp1","volume":"22","author":"Li","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2009.02.006_bib13","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib14","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.drudis.2009.02.006_bib15","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/hmg\/10.17.1829","article-title":"Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease","volume":"10","author":"Wyttenbach","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib16","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","article-title":"Modulation of nucleosome dynamics in Huntington's disease","volume":"16","author":"Stack","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib17","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nature06022","article-title":"Global changes to the ubiquitin system in Huntington's disease","volume":"448","author":"Bennett","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2009.02.006_bib18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/hmg\/11.9.1107","article-title":"Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy","volume":"11","author":"Ravikumar","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib19","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMra022366","article-title":"Apoptosis and caspases in neurodegenerative diseases","volume":"348","author":"Friedlander","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2009.02.006_bib20","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib21","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.022631799","article-title":"Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity","volume":"99","author":"Khoshnan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ejphar.2008.01.059","article-title":"Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases","volume":"585","author":"Wilhelmus","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2009.02.006_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pharmthera.2005.04.008","article-title":"The therapeutic role of creatine in Huntington's disease","volume":"108","author":"Ryu","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2009.02.006_bib24","doi-asserted-by":"crossref","first-page":"8892","DOI":"10.1073\/pnas.95.15.8892","article-title":"Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects","volume":"95","author":"Matthews","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2009.02.006_bib26","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib27","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bjp.0705662","article-title":"Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease","volume":"141","author":"Toulmond","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2009.02.006_bib29","first-page":"653","article-title":"Drug discovery and development for Huntington's disease\u2014an orphan indication with high medical need","volume":"11","author":"Heitz","year":"2008","journal-title":"IDrugs"},{"key":"10.1016\/j.drudis.2009.02.006_bib30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.nurt.2008.01.003","article-title":"Neuroprotection for Huntington's disease: ready, set, slow","volume":"5","author":"Hersch","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2009.02.006_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0092-8674(00)80514-0","article-title":"Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo","volume":"90","author":"Scherzinger","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2009.02.006_bib32","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1073\/pnas.110138997","article-title":"Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy","volume":"97","author":"Heiser","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","article-title":"Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease","volume":"10","author":"Tanaka","year":"2004","journal-title":"Nat. Med."},{"issue":"Suppl. 4","key":"10.1016\/j.drudis.2009.02.006_bib34","doi-asserted-by":"crossref","first-page":"16400","DOI":"10.1073\/pnas.182426599","article-title":"Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay","volume":"99","author":"Heiser","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib35","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1021\/jm980202u","article-title":"Riluzole series. Synthesis and in vivo \u2018antiglutamate\u2019 activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines","volume":"42","author":"Jimonet","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2009.02.006_bib36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/abio.2001.5217","article-title":"A microtiter plate assay for polyglutamine aggregate extension","volume":"295","author":"Berthelier","year":"2001","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.drudis.2009.02.006_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-6-1","article-title":"Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation","volume":"6","author":"Wang","year":"2005","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1089\/adt.2007.083","article-title":"Optimization of a polyglutamine aggregation inhibitor peptide (QBP1) using a thioflavin T fluorescence assay","volume":"5","author":"Hamuro","year":"2007","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.drudis.2009.02.006_bib39","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1074\/jbc.275.14.10437","article-title":"Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening","volume":"275","author":"Nagai","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2009.02.006_bib40","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1073\/pnas.97.4.1589","article-title":"Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins","volume":"97","author":"Krobitsch","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1073\/pnas.0408936102","article-title":"A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/mthe.2000.0235","article-title":"Gene transfer methods for CNS organotypic cultures: a comparison of three nonviral methods","volume":"3","author":"Murphy","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2009.02.006_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molbrainres.2003.11.011","article-title":"A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease","volume":"121","author":"Murphy","year":"2004","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.drudis.2009.02.006_bib44","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/138620708783877753","article-title":"High throughput screening for neurodegeneration and complex disease phenotypes","volume":"11","author":"Varma","year":"2008","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.drudis.2009.02.006_bib45","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1006\/nbdi.2001.0438","article-title":"Inhibition of polyglutamine aggregation in R6\/2 HD brain slices-complex dose-response profiles","volume":"8","author":"Smith","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2009.02.006_bib46","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0896-6273(03)00697-4","article-title":"A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor","volume":"40","author":"Pollitt","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2009.02.006_bib47","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1128\/MCB.00079-08","article-title":"Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation","volume":"28","author":"Shao","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2009.02.006_bib48","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/hmg\/ddl135","article-title":"Biologically active molecules that reduce polyglutamine aggregation and toxicity","volume":"15","author":"Desai","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brainresbull.2007.08.005","article-title":"Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death","volume":"75","author":"Gong","year":"2008","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.drudis.2009.02.006_bib50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jneumeth.2008.02.007","article-title":"High throughput quantification of mutant huntingtin aggregates","volume":"171","author":"Scotter","year":"2008","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.drudis.2009.02.006_bib51","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1471-4159.2007.05032.x","article-title":"Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease","volume":"104","author":"Weiss","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2009.02.006_bib52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.65","article-title":"Small-molecule aggregates inhibit amyloid polymerization","volume":"4","author":"Feng","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drudis.2009.02.006_bib53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nchembio883","article-title":"Small molecules enhance autophagy and reduce toxicity in Huntington's disease models","volume":"3","author":"Sarkar","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drudis.2009.02.006_bib54","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1073\/pnas.2628045100","article-title":"A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila","volume":"100","author":"Apostol","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1087057107299428","article-title":"Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments","volume":"12","author":"Coufal","year":"2007","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.drudis.2009.02.006_bib56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuron.2005.06.005","article-title":"p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease","volume":"47","author":"Bae","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2009.02.006_bib57","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/emboj.2008.23","article-title":"Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor","volume":"27","author":"Yamanaka","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.drudis.2009.02.006_bib58","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1074\/jbc.M705306200","article-title":"RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells","volume":"283","author":"Doi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2009.02.006_bib59","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1523\/JNEUROSCI.3493-03.2004","article-title":"CRE-mediated transcription is increased in Huntington's disease transgenic mice","volume":"24","author":"Obrietan","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib60","doi-asserted-by":"crossref","first-page":"16672","DOI":"10.1074\/jbc.M511648200","article-title":"Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective","volume":"281","author":"Qiu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2009.02.006_bib61","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1074\/jbc.M310226200","article-title":"Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis","volume":"279","author":"Sugars","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2009.02.006_bib62","doi-asserted-by":"crossref","first-page":"10720","DOI":"10.1523\/JNEUROSCI.2126-08.2008","article-title":"Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner","volume":"28","author":"Benn","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pneurobio.2007.02.005","article-title":"Drug targeting of dysregulated transcription in Huntington's disease","volume":"83","author":"Kazantsev","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.drudis.2009.02.006_bib64","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.nbd.2005.05.017","article-title":"Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment","volume":"20","author":"Zala","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2009.02.006_bib65","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/hmg\/ddh045","article-title":"A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor","volume":"13","author":"Piccioni","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nbd.2004.04.001","article-title":"A cell-based screen for drugs to treat Huntington's disease","volume":"16","author":"Aiken","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2009.02.006_bib67","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.nbd.2005.03.026","article-title":"Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model","volume":"20","author":"Wang","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2009.02.006_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nchembio852","article-title":"Selective inhibitors of death in mutant huntingtin cells","volume":"3","author":"Varma","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drudis.2009.02.006_bib69","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1523\/JNEUROSCI.20-10-03705.2000","article-title":"Wild-type huntingtin protects from apoptosis upstream of caspase-3","volume":"20","author":"Rigamonti","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib70","article-title":"Neuronal transfection using particle-mediated gene transfer","author":"Lo","year":"2001","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib71","doi-asserted-by":"crossref","first-page":"10461","DOI":"10.1073\/pnas.0600930103","article-title":"Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform","volume":"103","author":"Wang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib72","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1073\/pnas.96.1.179","article-title":"Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron","volume":"96","author":"Faber","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2009.02.006_bib73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0896-6273(00)80573-5","article-title":"Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons","volume":"21","author":"Jackson","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2009.02.006_bib74","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1093\/hmg\/ddg271","article-title":"Fly models of Huntington's disease","volume":"2","author":"Marsh","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib75","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1523\/JNEUROSCI.3001-05.2005","article-title":"CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo","volume":"25","author":"Miller","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib76","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1371\/journal.pone.0000504","article-title":"Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans","volume":"2","author":"Voisine","year":"2007","journal-title":"PLOS ONE"},{"key":"10.1016\/j.drudis.2009.02.006_bib77","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","article-title":"Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease","volume":"17","author":"Pallos","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib78","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/hmg\/ddg144","article-title":"Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila","volume":"12","author":"Nagai","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib79","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1471-4159.2008.05463.x","article-title":"Zebrafish as a new animal model for movement disorders","volume":"106","author":"Flinn","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2009.02.006_bib80","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nchembio.79","article-title":"Novel targets for Huntington's disease in an mTOR-independent autophagy pathway","volume":"4","author":"Williams","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drudis.2009.02.006_bib81","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/263244a0","article-title":"Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea","volume":"263","author":"Coyle","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2009.02.006_bib82","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1006\/exnr.1993.1197","article-title":"Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome","volume":"124","author":"Roberts","year":"1993","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2009.02.006_bib83","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1523\/JNEUROSCI.13-10-04181.1993","article-title":"Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid","volume":"13","author":"Beal","year":"1993","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib84","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1471-4159.2005.03515.x","article-title":"3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease","volume":"95","author":"Brouillet","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2009.02.006_bib85","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrn1386","article-title":"Experimental therapeutics in transgenic mouse models of Huntington's disease","volume":"5","author":"Beal","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib86","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2009.02.006_bib87","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","article-title":"Delaying the onset of Huntington's in mice","volume":"404","author":"Van Dellen","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2009.02.006_bib88","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.nbd.2006.12.010","article-title":"Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain","volume":"26","author":"Van Raamsdonk","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2009.02.006_bib89","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.expneurol.2004.01.003","article-title":"Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice","volume":"187","author":"Schilling","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2009.02.006_bib90","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/hmg\/ddl125","article-title":"Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice","volume":"15","author":"Lloret","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib91","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10094","article-title":"Environmental enrichment slows disease progression in R6\/2 Huntington's disease mice","volume":"51","author":"Hockly","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2009.02.006_bib92","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib93","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/hmg\/ddg075","article-title":"Transgenic rat model of Huntington's disease","volume":"12","author":"von Horsten","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib94","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2009.02.006_bib95","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib96","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1523\/JNEUROSCI.22-18-08266.2002","article-title":"Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice","volume":"22","author":"Menalled","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2009.02.006_bib97","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/9.4.503","article-title":"Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice","volume":"9","author":"Wheeler","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib98","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/10.2.137","article-title":"Neurological abnormalities in a knock-in mouse model of Huntington's disease","volume":"10","author":"Lin","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2009.02.006_bib99","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nature06975","article-title":"Towards a transgenic model of Huntington's disease in a non-human primate","volume":"453","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2009.02.006_bib100","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrd2410","article-title":"Target deconvolution strategies in drug discovery","volume":"6","author":"Terstappen","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2009.02.006_bib101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/138620708783877744","article-title":"Discovery of novel targets with high throughput RNA interference screening","volume":"11","author":"Kassner","year":"2008","journal-title":"Comb. Chem. High Throughput Screen."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644609000622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644609000622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:04:28Z","timestamp":1761221068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644609000622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":101,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S1359644609000622"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2009.02.006","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule drug discovery for Huntington's Disease","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2009.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}